Cargando…

Predicting the efficacy of new coronavirus vaccines – Are neutralising antibodies enough?

Detalles Bibliográficos
Autor principal:	Miller, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044976/ https://www.ncbi.nlm.nih.gov/pubmed/35489231 http://dx.doi.org/10.1016/j.ebiom.2022.104034

Ejemplares similares

Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
por: Nadesalingam, Angalee, et al.
Publicado: (2021)

Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2
por: Strugnell, Richard, et al.
Publicado: (2021)

Predictive tools in psychosis: what is ‘good enough’?
por: Seyedsalehi, Aida, et al.
Publicado: (2023)

Offline: Facts are not enough
por: Horton, Richard
Publicado: (2020)

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

New realm of placenta accreta spectrum disorder: are we doing enough?
por: Pandey, Anuj Kumar, et al.
Publicado: (2023)

“Enough is Enough”: tackling sexism, sexual harassment, and power abuse in Spain's academia and healthcare sector
por: Paniello-Castillo, Blanca, et al.
Publicado: (2023)

Forty years of The Selfish Gene are not enough
por: Yanai, Itai, et al.
Publicado: (2016)

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
por: Berry, Jody D, et al.
Publicado: (2004)

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough
por: Cao, Bin, et al.
Publicado: (2020)

Close, but not close enough
por: Daemen, J.
Publicado: (2014)

Vitamin D Supplementation as Add-on Therapy in Multiple Sclerosis—Balance between Benefit and Risk?: A Commentary on Vitamin D Supplementation in Central Nervous System Demyelinating Disease—Enough Is Enough
por: Goischke, Hans-Klaus
Publicado: (2019)

Sex differences in COVID-19 case fatality: do we know enough?
por: Dehingia, Nabamallika, et al.
Publicado: (2021)

Reaching the theoretical herd immunity threshold in Iquitos, Peru: are seroprevalence data enough?
por: Chenet, Stella M, et al.
Publicado: (2021)

New international guidance on quality, safety and efficacy of DNA vaccines
por: Beasley, David W. C.
Publicado: (2020)

Universal coronavirus vaccines: the time to start is now
por: Giurgea, Luca T., et al.
Publicado: (2020)

Mechanisms of Rhinovirus Neutralisation by Antibodies
por: Touabi, Lila, et al.
Publicado: (2021)

Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?
por: Modjarrad, Kayvon, et al.
Publicado: (2020)

Coronavirus Disease 2019 and Primary Antibody Deficiencies. Comment on Milota et al. Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies. Pathogens 2023, 12, 109
por: Özdemir, Öner
Publicado: (2023)

Three-dose vaccination elicits neutralising antibodies against omicron
por: Wu, Mary, et al.
Publicado: (2022)

First clinical trial of a MERS coronavirus DNA vaccine
por: Yoon, In-Kyu, et al.
Publicado: (2019)

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses
por: Spruth, Martin, et al.
Publicado: (2006)

Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
por: Palmeira, Vitória Andrade, et al.
Publicado: (2020)

Virus Neutralisation: New Insights from Kinetic Neutralisation Curves
por: Magnus, Carsten
Publicado: (2013)

Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
por: Yadav, Pragya D, et al.
Publicado: (2022)

Post-coronavirus disease syndrome and disseminated microthrombosis: the role of the von Willebrand factor and antiphospholipid antibodies
por: Sieiro-Santos, Cristiana, et al.
Publicado: (2021)

COVID-19 vaccines: neutralizing antibodies and the alum advantage
por: Hotez, Peter J., et al.
Publicado: (2020)

Evaluation of a Pseudotyped Virus Neutralisation Test for the Measurement of Equine Influenza Virus-Neutralising Antibody Responses Induced by Vaccination and Infection
por: Kinsley, Rebecca, et al.
Publicado: (2020)

Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
por: Carr, Edward J, et al.
Publicado: (2022)

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids
por: Handisurya, A, et al.
Publicado: (2016)

Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines
por: Wang, Youchun
Publicado: (2021)

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
por: Carr, Edward J, et al.
Publicado: (2021)

Neutralising Antibodies against Ricin Toxin
por: Prigent, Julie, et al.
Publicado: (2011)

The antibody response of haematological malignancies to COVID-19 infection and vaccination
por: Seebacher, Nicole A.
Publicado: (2022)

Vaccine efficacy and immune interference: co-administering COVID-19 and influenza vaccines
por: Altmann, Daniel M, et al.
Publicado: (2022)

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
por: Olliaro, Piero, et al.
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021)

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
por: Lim, Sean H, et al.
Publicado: (2021)

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses
por: Liniger, Matthias, et al.
Publicado: (2008)

COVID-19 vaccine trials should seek worthwhile efficacy
por: Krause, Philip, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9locca9hms8m779ctcujicqvgc